End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021

September 2021 | 44 pages | ID: E8F2C6A98A1FEN
Global Markets Direct

Abstracts

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Drugs In Development, 2021, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 1, 1, 1 and 1 respectively.

End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
Acacia Pharma Ltd
Aronora Inc
Bayer AG
BioAegis Therapeutics Inc
Daiichi Sankyo Co Ltd
Ionis Pharmaceuticals Inc
KidneyCure Ltd
VESSL Therapeutics Ltd
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
3DAN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amisulpride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXILRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osocimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TDO2 for End-Stage Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2021: Aronora reports positive topline data from phase 2 study of AB023 in hemodialysis patients
Dec 02, 2020: Aronora announces clinical data to be presented at the 62nd American Society of Hematology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Acacia Pharma Ltd, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Daiichi Sankyo Co Ltd, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals Inc, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, 2021
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021